Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Herrlinger

Showing results (111-120 of 243) with videos related to

Pageof 25
Sort By:
Neuro-Oncology Advances|June 27, 2025
Second-line temozolomide in first recurrent MGMT-methylated glioblastoma after lomustine/temozolomide: Efficacy and safetyThomas Zeyen, Antonia Treiber, Matthias Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomideMoritz Stuplich, Dariusch R Hadizadeh, Klaus Kuchelmeister, et al.
Neurosurgical Review|January 2, 2023
Unplanned intensive care unit readmission after surgical treatment in patients with newly diagnosed glioblastoma - forfeiture of surgically achieved advantages?Felix Lehmann, Anna-Laura Potthoff, Valeri Borger, et al.
Journal of Cancer Research and Clinical Oncology|November 23, 2019
Bevacizumab versus alkylating chemotherapy in recurrent glioblastomaKatharina Seystahl, Bettina Hentschel, Sarah Loew, et al.
Neuro-Oncology Practice|July 19, 2021
Chemotherapy for adult patients with spinal cord gliomasDorothee Gramatzki, Jörg Felsberg, Bettina Hentschel, et al.
Frontiers in Oncology|November 15, 2021
Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for GlioblastomaGustavo R Sarria, Zuzanna Smalec, Thomas Muedder, et al.
Journal of Neuro-Oncology|October 3, 2023
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trialJohannes Weller, Thomas Zeyen, Niklas Schäfer, et al.
Neurosurgical Review|June 29, 2023
Incurring detriments of unplanned readmission to the intensive care unit following surgery for brain metastasisJustus August Schweppe, Anna-Laura Potthoff, Muriel Heimann, et al.
Cancers|October 14, 2022
Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC)Inja Ilic, Anna-Laura Potthoff, Valeri Borger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PETSied Kebir, Rolf Fimmers, Norbert Galldiks, et al.
Pageof 25

Showing results (111-120 of 243) with videos related to

Sort By:
Pageof 25
Neuro-Oncology Advances|June 27, 2025
Second-line temozolomide in first recurrent MGMT-methylated glioblastoma after lomustine/temozolomide: Efficacy and safetyThomas Zeyen, Antonia Treiber, Matthias Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomideMoritz Stuplich, Dariusch R Hadizadeh, Klaus Kuchelmeister, et al.
Neurosurgical Review|January 2, 2023
Unplanned intensive care unit readmission after surgical treatment in patients with newly diagnosed glioblastoma - forfeiture of surgically achieved advantages?Felix Lehmann, Anna-Laura Potthoff, Valeri Borger, et al.
Journal of Cancer Research and Clinical Oncology|November 23, 2019
Bevacizumab versus alkylating chemotherapy in recurrent glioblastomaKatharina Seystahl, Bettina Hentschel, Sarah Loew, et al.
Neuro-Oncology Practice|July 19, 2021
Chemotherapy for adult patients with spinal cord gliomasDorothee Gramatzki, Jörg Felsberg, Bettina Hentschel, et al.
Frontiers in Oncology|November 15, 2021
Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for GlioblastomaGustavo R Sarria, Zuzanna Smalec, Thomas Muedder, et al.
Journal of Neuro-Oncology|October 3, 2023
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trialJohannes Weller, Thomas Zeyen, Niklas Schäfer, et al.
Neurosurgical Review|June 29, 2023
Incurring detriments of unplanned readmission to the intensive care unit following surgery for brain metastasisJustus August Schweppe, Anna-Laura Potthoff, Muriel Heimann, et al.
Cancers|October 14, 2022
Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC)Inja Ilic, Anna-Laura Potthoff, Valeri Borger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PETSied Kebir, Rolf Fimmers, Norbert Galldiks, et al.
Pageof 25